Navigation Links
Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
Date:10/28/2013

LA JOLLA, Calif., Oct. 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of an undisclosed oncology target by AstraZeneca under the strategic alliance to discover, develop, and commercialize microRNA therapeutics.  Regulus and AstraZeneca continue to collaborate on three exclusive microRNA targets in cardiovascular and metabolic diseases and oncology.

"We are very pleased with the successful relationship we have built with AstraZeneca and their selection of a validated microRNA target for oncology indications," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus.  "In the last year, we have made significant progress in advancing our drug discovery efforts against the portfolio of AstraZeneca targets.  With the support of AstraZeneca's drug development expertise and commitment to the RNA therapeutics field, we continue to harness our microRNA expertise to develop innovative, first-in-class treatment options for patients in need." 

In August 2012, Regulus and AstraZeneca formed a strategic alliance focused on three exclusive microRNA targets for cardiovascular and metabolic diseases and oncology, which includes Regulus' program targeting microRNA-33 for the treatment of atherosclerosis.  Under the terms of the alliance, Regulus will lead preclinical development and, if successful, could receive preclinical milestone payments.  AstraZeneca will lead and fund the clinical development and commercialization of these programs.  In addition, Regulus could also receive clinical milestones based on the successful development of microRNA therapies in each target area. Regulus is also eligible to receive significant launch
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
2. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
3. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
4. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
5. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
6. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
7. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
8. Regulus to Present at Future Leaders in the Biotech Industry Conference
9. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
10. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
11. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... N.Y. , Dec. 17, 2014  Northstar ... The Depository Trust Company (DTC) has made their ... Deposit Chill on the Company,s stock effective December ... Northstar,s common stock for depository and book entry ... the Company is now once again fully "DTC ...
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... Aug. 24 Curemark Founder and CEO Dr. Joan Fallon ... Sequencing 2009 Conference at Harvard Medical School on July 14th. ... this cutting-edge conclave is particularly significant, since epigenetics is the ... a change in the DNA sequence. Presenters at the session ...
... , EMERYVILLE, Calif., Aug. 21 ... NBY ), a clinical stage company developing non-antibiotic anti-infective compounds ... viral, and fungal infections, will deliver two poster presentations at the ... San Francisco, CA. The two poster presentations will describe results ...
Cached Medicine Technology:Curemark CEO Presents at Epigenomics Conference 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 3
(Date:12/22/2014)... Petersburg, FL (PRWEB) December 22, 2014 Christmas ... Sublime Beauty® has a fast and easy solution that will ... gift cards can be purchased from from $25 up to ... "We offer 100% customer satisfaction and a wide array of ... have no fees and no expiration dates. , Gift ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/21/2014)... 22, 2014 Recently, BambooFlooringChina.com, a famous ... woven bamboo flooring collection , and launched a bamboo ... promotion is valid until Jan. 30, 2015. , According ... is the hardest bamboo flooring available today; it has ... of traditional teak hardwoods. Strand woven bamboo is made ...
(Date:12/21/2014)... Gables, FL (PRWEB) December 21, 2014 When ... head lice, who do they call? The new answer is ... Blvd, Coral Gables FL 33134, their newest treatment center will ... this pest quickly, conveniently and without the use of harmful ... Opening is scheduled for January 1, 2015. Like the company’s ...
(Date:12/21/2014)... 2014 Recently, one of the best ... Prom Shop has introduced its new collection of ... big discounts on all its prom dresses & other ... insists on providing top quality dress products and great ... considered as one of the best prom dresses online ...
Breaking Medicine News(10 mins):Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2
... (AMS), which affects about half of those ascending to heights ... pulmonary or cerebral edema. ,The interest of the general ... past 25 years. This change is partly due to media ... In spite of these apparent changes, it is unknown whether ...
... deadly bird flu since it is still rampant in the region, ... ,"I think countries in this part of the world have ... it, the virus is still circulating," said Shigeru Omi, WHO's regional ... We remain concerned. We must avoid human transmission," he told reporters ...
... patients who have already gone blind in one eye ... and Therapeutics Bulletin (DTB). ,But that is ... (NICE), the body responsible for guiding the NHS on ... (Lucentis) and pegaptanib (Macugen) are licensed in the UK ...
... Biotechnology Co., Ltd. announced that a team led by ... completed a study to assess clinical efficacy, safety, ... for patients with peripheral vascular disease of the lower ... research and treatments for ataxia, cerebral palsy, spinal cord ...
... Those involved in biological weapons programs should be logically liable ... it seems to have happened in US and the Centers ... research laboratory at Texas A&M University to stop all work ... investigating reports of lab workers infected with the category B ...
... personnel involved in the Iraqi invasion of 2003 have ... published ahead of print in Occupational and Environmental Medicine. ... combat to pierce armoured vehicles, and spontaneously combusts on ... breathed in or eaten/drunk in contaminated food/water. ...
Cached Medicine News:Health News:Acute Mountain Sickness may Lead to Pulmonary or Cerebral Edema 2Health News:Bird Flu in Asia Still High Risk Says WHO Official 2Health News:Draft National Policy on Sight-saving Drugs unacceptable 2Health News:Adult Stem Cells Show Promise for Peripheral Vascular Disease 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 3Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 4
McDavid® Patella Knee Support helps relieve the symptoms of chondromalacia patellar subluxation and patellar tendonitis. Features two medial and two lateral spring-steel stays. 3/16" thick neopre...
... Exotec® Dual Instabilities Lite Lightweight mechanical ... patients with ACL, MCL or LCL ... tibia movement and reduce load on ... or add-ons. Supports the injured or ...
... Orthosis Custom-fitted static-progressive orthosis ... Goniometer version has calibrated ... metal contacts skin. Includes ... bag. One size fits ...
... Polyamide Hinge Wraparound design can ... fit. Multilock polyamide hinge prevents ... extension can be set for ... level. Provides medial/lateral support during ...
Medicine Products: